310 related articles for article (PubMed ID: 15203992)
1. The immune response to breast cancer, and the case for DC immunotherapy.
Allan CP; Turtle CJ; Mainwaring PN; Pyke C; Hart DN
Cytotherapy; 2004; 6(2):154-63. PubMed ID: 15203992
[TBL] [Abstract][Full Text] [Related]
2. Loading DCs with Ag.
Vari F; Hart DN
Cytotherapy; 2004; 6(2):111-21. PubMed ID: 15203987
[TBL] [Abstract][Full Text] [Related]
3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
4. DC in multiple myeloma immunotherapy.
Turtle CJ; Brown RD; Joshua DE; Hart DN
Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based vaccines in breast and gynaecologic cancer.
Hernando JJ; Park TW; Kuhn WC
Anticancer Res; 2003; 23(5b):4293-303. PubMed ID: 14666641
[TBL] [Abstract][Full Text] [Related]
6. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based vaccines: clinical applications in breast cancer.
Gelao L; Criscitiello C; Esposito A; De Laurentiis M; Fumagalli L; Locatelli MA; Minchella I; Santangelo M; De Placido S; Goldhirsch A; Curigliano G
Immunotherapy; 2014; 6(3):349-60. PubMed ID: 24762078
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells and their role in cancer immunotherapy.
Jalili A
Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
11. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
12. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
13. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
[TBL] [Abstract][Full Text] [Related]
15. Cancer vaccines for established cancer: how to make them better?
Andrews DM; Maraskovsky E; Smyth MJ
Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
[TBL] [Abstract][Full Text] [Related]
16. Immunizing against breast cancer: a new swing for an old sword.
Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A
Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells: tools and targets for antitumor vaccination.
den Brok MH; Nierkens S; Figdor CG; Ruers TJ; Adema GJ
Expert Rev Vaccines; 2005 Oct; 4(5):699-710. PubMed ID: 16221071
[TBL] [Abstract][Full Text] [Related]
18. The use of dendritic cells in cancer immunotherapy.
Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
